Healthcare Industry News: Genzyme
News Release - February 9, 2006
Genzyme Launches Key Test to Monitor Gleevec(R) ResistanceTwo Additional Personalized Medicine Tests Also Now Available
CAMBRIDGE, Mass., Feb. 9 (HSMN NewsFeed) -- Genzyme Corporation (Nasdaq: GENZ ) announced today the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were initially treated successfully will develop resistance during therapy. Genzyme's new BCR-ABL Mutation Analysis test will assist physicians in evaluating resistance to therapy and facilitate appropriate adjustments to treatment.
The molecular hallmark of CML is a mutation known as BCR-ABL. This mutation is the specific target for Gleevec and is found in 95 percent of patients with CML. In relapse patients, the majority of secondary mutations in the ABL portion of the gene correlate with treatment failure. Genzyme's new test detects all secondary BCR-ABL mutations and therefore predicts resistance to Gleevec.
"This is a very exciting time for leukemia patients and their caregivers because this test will provide them with more information about their disease and will give them the ability to personalize their treatment," said Mara Aspinall, president of Genzyme Genetics, the business unit of Genzyme Corp. focused on the research and development of high quality, complex testing services.
"We are pleased to offer another important predictive test that can play a critical role in the way oncologists and patients manage their cancer," she added. Genzyme recently launched several other personalized medicine tests in the areas of lung cancer and leukemia and lymphoma.
Because of its high efficacy and limited side effects, Gleevec as a first- line therapy is considered to have revolutionized long-term survival of patients with CML. Gleevec was approved by the U.S. Food and Drug Administration in May, 2001 as the first drug in a new class of molecular targeted therapies for CML. Over 90 percent of patients treated with Gleevec respond initially to treatment, and many experience a complete remission. However, four to five percent of these patients eventually develop resistance to the treatment and experience a relapse of their disease.
The discovery of the BCR-ABL mutations was made by researchers at the University of California at Los Angeles (UCLA) Jonsson Cancer Center in 2001, who are currently working to determine if the same mutations in patients with CML may also lead to resistance to newer investigational treatments.
In October, Genzyme announced that it entered into a license agreement with UCLA to obtain exclusive, worldwide diagnostic rights to UCLA's discovery of gene mutations believed to be associated with drug resistance to Gleevec.
A Commitment to Personalized Medicine -- EGFR FISH & JAK2 Expand Cancer Menu
Genzyme Genetics offers two tests that identify non-small cell lung cancer (NSCLC) patients likely to respond to therapies. The presence of epidermal growth factor receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva® (erlotinib) and IRESSA® (gefitinib), used in treating this deadly form of cancer. Genzyme now offers EGFR by FISH (fluorescence in-situ hybridization), which detects over amplification of the EGFR gene. This new test complements Genzyme's EGFR Mutation Assay, which also detects the presence of EGFR in patients with NSCLC.
Genzyme has also made available a new assay that detects a mutation in the Janus kinase 2 (JAK2) gene common in chronic myeloproliferative disorders (MPDs). MPDs are a large group of pathogenetically related diseases (including CML) characterized by proliferation of one or more myeloid cell lines in the bone marrow and increased numbers of mature and immature cells in the peripheral blood diseases. This new JAK2 test allows for the classification, diagnosis, and potential treatment of these diseases.
About Chronic Myeloid Leukemia
Chronic myeloid leukemia is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
The American Cancer Society estimated that there were approximately 4,600 new cases of CML diagnosed in 2005. Approximately 25,000 CML patients are living in remission on therapy in the U.S. today. The average age of people with CML is around 50 years.
About Genzyme Genetics
Genzyme Genetics is a leading, nationwide provider of high-quality, complex testing services for physicians and their patients. With CLIA- certified laboratories and counseling facilities located across the U.S., Genzyme Genetics offers extensive diagnostic testing services, supported by innovative technology and a commitment to quality service and trusted information. Genzyme Genetics is a business unit of Genzyme Corporation.
About Genzyme Corporation
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme's founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,000 employees in locations spanning the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.
This press release contains forward-looking statements, including statements regarding the marketing and sales of a diagnostic test to detect secondary BCR-ABL mutations and monitor resistance in CML patients prior to and during treatment with Gleevec, the number of patients likely to develop resistance to Gleevec, the ability of the CML markers test to predict patient relapse, identify patients who are likely to respond to Gleevec, and identify patients likely to develop resistance to Gleevec, as well as Genzyme Genetics' expectations regarding the additional information and ability to personalize treatment resulting from doctors' access to a CML marker diagnostic test. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, scientific, technical and manufacturing issues that could prevent the sales and marketing of a CML markers diagnostic test as contemplated, the failure of a CML markers diagnostic test to produce diagnostic results as anticipated, the commercial acceptance of CML markers diagnostic tests, including the acceptance of a CML test at price levels that are economically viable for Genzyme Genetics, and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Factors Affecting Future Operating Results" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending September 30, 2005. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. All statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.
Genzyme® is a registered trademark of Genzyme Corporation. Gleevec® is a registered trademark of Novartis. All rights reserved.
Genzyme's press releases and other company information are available at http://www.Genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.